|
Title
|
|
|
|
The role of targeted therapy for gastrointestinal tumors
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Expert review of gastroenterology & hepatology
| |
|
Publication
|
|
|
|
London
:
Expert reviews
,
2014
| |
|
ISSN
|
|
|
|
1747-4124
1747-4132
| |
|
DOI
|
|
|
|
10.1586/17474124.2014.922870
| |
|
Volume/pages
|
|
|
|
8
:8
(2014)
, p. 875-885
| |
|
ISI
|
|
|
|
000347182600005
| |
|
Pubmed ID
|
|
|
|
24957206
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|